25602 Improvements and response achievement in PASI subscale domains for head scaling and erythema in apremilast-treated patients with moderate to severe plaque psoriasis of the scalp: Results from the STYLE study - 07/08/21
Doi : 10.1016/j.jaad.2021.06.276
Le texte complet de cet article est disponible en PDF.
Le texte complet de cet article est disponible en PDF.
| Commercial Disclosure: 100% of this abstract was sponsored by Amgen Inc. This study was funded by Celgene. Additional analyses were funded by Amgen Inc. |
© 2021
Publié par Elsevier Masson SAS.
Vol 85 - N° 3S
P. AB63 - septembre 2021 Retour au numéro
Article précédent
- 25597 Improvements in scalp and nail psoriasis with apremilast treatment in patients with moderate to severe plaque psoriasis with and without a history of psoriatic arthritis
- Jeffrey Crowley, Melinda Gooderham, Sven Richter, Rebecca Shi, Kristian Reich
- 25603 Improvement in scalp psoriasis and quality of life with apremilast in patients with moderate to severe scalp psoriasis regardless of prior systemic treatment: Results from the phase 3, randomized STYLE study
- Yao Wang, Linda Stein Gold, Mark Lebwohl, Bruce Strober, Zuoshun Zhang, Abby Van Voorhees
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?